Posts Tagged ‘Vedotin’

Seattle Genetics and Mill? Millennium report data? If Phase II registration pending initial positive Vedotin Brentuximab (SGN-35) if RecA? Da. . .

Seattle Genetics and Millennium Report Positive Data from Phase II Trial of Brentuximab Vedotin (SGN-35) in Relapsed …
ORLANDO, Fla.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced positive data from a phase II clinical trial of single-agent brentuximab vedotin (SGN-35) in relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin is …

Read more on Business Wire



Related Blogs

Seattle Genetics and reprocessing Millennium positive report data Brentuximab Vedotin (SGN-35) in lymphoma

Seattle Genetics and Millennium Report Positive Data on Retreatment with Brentuximab Vedotin (SGN-35) in Lymphoma
Seattle Genetics, Inc. (Nasdaq:SGEN) and Millennium: The Takeda Oncology Company, …

Read more on Finanzen.net



Related Blogs

Contact Us | Terms of Use | Privacy Statement